Biomerica (BMRA) Competitors $0.33 +0.00 (+0.83%) (As of 11:15 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends BMRA vs. ACXP, IBIO, GLYC, PIRS, SPRB, ENLV, MIRA, CYTH, UBX, and XCURShould you be buying Biomerica stock or one of its competitors? The main competitors of Biomerica include Acurx Pharmaceuticals (ACXP), iBio (IBIO), GlycoMimetics (GLYC), Pieris Pharmaceuticals (PIRS), Spruce Biosciences (SPRB), Enlivex Therapeutics (ENLV), MIRA Pharmaceuticals (MIRA), Cyclo Therapeutics (CYTH), Unity Biotechnology (UBX), and Exicure (XCUR). These companies are all part of the "pharmaceutical products" industry. Biomerica vs. Acurx Pharmaceuticals iBio GlycoMimetics Pieris Pharmaceuticals Spruce Biosciences Enlivex Therapeutics MIRA Pharmaceuticals Cyclo Therapeutics Unity Biotechnology Exicure Biomerica (NASDAQ:BMRA) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation. Is BMRA or ACXP more profitable? Acurx Pharmaceuticals has a net margin of 0.00% compared to Biomerica's net margin of -111.89%. Biomerica's return on equity of -84.62% beat Acurx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Biomerica-111.89% -84.62% -62.72% Acurx Pharmaceuticals N/A -392.36%-223.78% Does the media refer more to BMRA or ACXP? In the previous week, Acurx Pharmaceuticals had 14 more articles in the media than Biomerica. MarketBeat recorded 15 mentions for Acurx Pharmaceuticals and 1 mentions for Biomerica. Acurx Pharmaceuticals' average media sentiment score of 0.61 beat Biomerica's score of 0.00 indicating that Acurx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomerica 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Acurx Pharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, BMRA or ACXP? Biomerica has higher revenue and earnings than Acurx Pharmaceuticals. Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Biomerica, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiomerica$5.41M1.02-$5.98M-$0.37-0.88Acurx PharmaceuticalsN/AN/A-$14.58M-$1.09-1.19 Do analysts recommend BMRA or ACXP? Acurx Pharmaceuticals has a consensus price target of $12.00, indicating a potential upside of 823.01%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Acurx Pharmaceuticals is more favorable than Biomerica.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomerica 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Acurx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, BMRA or ACXP? Biomerica has a beta of -1.13, indicating that its share price is 213% less volatile than the S&P 500. Comparatively, Acurx Pharmaceuticals has a beta of -1.73, indicating that its share price is 273% less volatile than the S&P 500. Does the MarketBeat Community prefer BMRA or ACXP? Biomerica received 124 more outperform votes than Acurx Pharmaceuticals when rated by MarketBeat users. However, 92.86% of users gave Acurx Pharmaceuticals an outperform vote while only 67.82% of users gave Biomerica an outperform vote. CompanyUnderperformOutperformBiomericaOutperform Votes13767.82% Underperform Votes6532.18% Acurx PharmaceuticalsOutperform Votes1392.86% Underperform Votes17.14% Do institutionals and insiders believe in BMRA or ACXP? 22.3% of Biomerica shares are held by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 15.0% of Biomerica shares are held by insiders. Comparatively, 29.6% of Acurx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryBiomerica beats Acurx Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Biomerica News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMRA vs. The Competition Export to ExcelMetricBiomericaDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.50M$2.21B$5.08B$8.80BDividend YieldN/A0.75%5.02%4.07%P/E Ratio-0.883.9191.2813.60Price / Sales1.0240.841,226.2187.40Price / CashN/A14.8239.4536.27Price / Book0.843.076.906.33Net Income-$5.98M$29.98M$118.83M$225.93M7 Day Performance-7.10%-1.67%-1.92%-0.96%1 Month Performance0.62%-10.46%-3.75%1.06%1 Year Performance-61.53%-15.85%31.37%26.59% Biomerica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMRABiomericaN/A$0.33+0.8%N/A-64.4%$5.50M$5.41M-0.8860News CoverageGap DownACXPAcurx Pharmaceuticals2.3848 of 5 stars$1.30-6.5%$12.00+823.0%-61.6%$21.96MN/A0.003Short Interest ↓Analyst RevisionNews CoverageGap UpIBIOiBio1.3721 of 5 stars$2.26+3.2%$4.30+90.3%N/A$20.68M$220,000.000.00100Positive NewsGap UpGLYCGlycoMimetics3.442 of 5 stars$0.32-4.0%$10.00+3,057.6%-78.4%$20.42M$10,000.000.0050Gap DownPIRSPieris Pharmaceuticals1.6293 of 5 stars$15.39-3.9%N/A-10.4%$20.32M$42.81M-1.32140Analyst UpgradeNews CoverageSPRBSpruce Biosciences2.9764 of 5 stars$0.49flat$4.00+716.3%-64.0%$20.24M$10.09M0.0020Gap DownENLVEnlivex Therapeutics3.0693 of 5 stars$0.93-4.7%$6.00+545.2%-42.9%$19.91MN/A0.0070News CoverageGap UpMIRAMIRA Pharmaceuticals1.6713 of 5 stars$1.20-5.1%$14.00+1,066.6%-72.8%$19.87MN/A0.002CYTHCyclo Therapeutics2.7699 of 5 stars$0.69-3.0%$0.95+38.2%-47.9%$19.78M$1.08M0.009News CoverageGap DownUBXUnity Biotechnology3.6114 of 5 stars$1.16-1.1%$8.00+591.0%-42.1%$19.51M$240,000.000.0060XCURExicure1.8025 of 5 stars$8.76-21.7%N/A+1,914.4%$19.01M$28.83M-4.9550News CoverageGap Down Related Companies and Tools Related Companies Acurx Pharmaceuticals Alternatives iBio Alternatives GlycoMimetics Alternatives Pieris Pharmaceuticals Alternatives Spruce Biosciences Alternatives Enlivex Therapeutics Alternatives MIRA Pharmaceuticals Alternatives Cyclo Therapeutics Alternatives Unity Biotechnology Alternatives Exicure Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BMRA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomerica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomerica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
